Ryusuke Sakamoto General Manager, Business Development Department
Sanwa Kagaku Kenkyusho is a valued member of the Suzuken Group, specializing in pharmaceuticals and diagnostics. Through our business development activities, we are committed to realizing our vision: "Patient-friendly 'medicines' for people around the world." Also, We have been addressing the issue of 'drug loss' in Japan-where drugs approved in the U.S. and/or Europe are not available in Japan- We have introduced the "J-Entry Consortium", a new market entry option. Our strength lies not only in offering traditional licensing structures but also in providing diverse partnership opportunities tailored to different needs. Let's discuss how we can collaborate!
Phase 2 ~ Phase 3 (With data on efficacy andsafety in clinical trials for the target indications)
2nd Priority
GLP ~ Phase 1
3rd Priority
Phase 2 ~ Phase 3 (Without data on efficacy and safety in clinical trials for the target indications)
Assets that are considered to have clear clinical positioning and competitive advantages
J-ENTRY Consortium
We offer a unique solution-the J-ENTRY Consortium (JEC)-to facilitate entry into the Japanese market. In collaboration with Suzuken (Distributor), EPS Group (CRO), and Bushu Pharma (CDMO), we are committed to addressing the issue of 'drug loss.' JEC provides a comprehensive, one-stop service for entering the Japanese market, covering the entire process from drug development and J-NDA submission for marketing authorization (MA) to sales, marketing, and distribution.
One-stop solution by a three-company collaboration
In February 2022, we entered into an exclusive licensing agreement with Crinetics Pharmaceuticals, Inc. for the development and commercialization of paltusotine in Japan. Paltusotine is Crinetics' investigational, orally available, once-daily, non-peptide somatostatin receptor type 2 (SST2) agonist, being evaluated as a treatment for acromegaly and carcinoid syndrome in neuroendocrine tumors. We are currently conducting a local Phase 3 trial for acromegaly in Japan, while Crinetics has successfully completed two global Phase 3 trials for acromegaly and submitted a New Drug Application (NDA) in the United States in September 2024.
EA Pharma Co., Ltd.
In March 2014, we entered into an exclusive licensing agreement with Ajinomoto Pharmaceuticals Co., Ltd. (now EA Pharma Co., Ltd.) for the development and commercialization rights of Upacicalcet in Japan for secondary hyperparathyroidism (SHPT) in patients undergoing hemodialysis. At the time, the asset was in the non-clinical stage. We successfully advanced all aspects of development, including CMC, non-clinical, and clinical studies, leading to marketing approval from the Ministry of Health, Labour and Welfare (MHLW) in August 2021. Since then, we have been commercializing the product under the name Upasita® Injection Syringe for Dialysis in Japan, contributing to improved treatment for dialysis patients suffering from SHPT.
Nissan Chemical Industries, Ltd.
Sanwa Kagaku Kenkyusho and Nissan Chemical have successfully discovered a preclinical antisense candidate under the discovery collaboration agreement established in March 2019. Building on this achievement, our team and Nissan Chemical have decided to expand their strategic collaboration to develop additional oligonucleotide therapeutic programs. Under this new collaboration, our team and Nissan Chemical are jointly conducting drug discovery research to identify novel oligonucleotide therapeutics. Nissan Chemical is responsible for designing and synthesizing oligonucleotide molecules targeting areas selected by both parties, while we oversee efficacy and toxicity studies.
Partnering
We have engaged in partnership agreements with numerous companies both domestically and internationally.
Our Pharmaceutical Business Partners
Our Diagnostic Business Partners
OSDrC® Business Partners
Our Other Business Partners
Our Business
Our website uses cookies to check usage, for convenience, and to maintain and improve the quality of our website. It should be noted that cookies do not collect or identify personal information.
For more information, please refer to our Cookie Policy.
Thank you for visiting the Sanwa Kagaku Kenkyusho's website.
You will now be redirected to an external website.
Site Map
Japanese
![Designated Marketing Authorization Holder(DMAH)↔Licensor[Development Phase→J-NDA〜MA→Commercialization]Providing all capabilities under your Strategy](/en/business/item/partnering/pic_01-sp.png)
